Terms: = Pancreatic cancer AND JAK3, L-JAK, 3718, ENSG00000105639, P52333, JAKL, JAK-3, LJAK, JAK3_HUMAN AND Prognosis
3 results:
1. Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in pancreatic Ductal Adenocarcinoma Microenvironment.
Yin Z; Chen S
Pancreas; 2022 Oct; 51(9):1235-1247. PubMed ID: 37078951
[TBL] [Abstract] [Full Text] [Related]
2. Integrated Genomic and Immunophenotypic Classification of pancreatic cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
[No Abstract] [Full Text] [Related]
3. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced pancreatic cancer: A Systematic Review and Meta-Analysis.
Chiramel J; Backen AC; Pihlak R; Lamarca A; Frizziero M; Tariq NU; Hubner RA; Valle JW; Amir E; McNamara MG
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28445400
[TBL] [Abstract] [Full Text] [Related]
